AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36052222 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLF patients at enrollment (n=unknown)
Number of subjects: 1736
Study 36052222 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable decompensated cirrhosis patients (n=251)
Number of subjects: 1736
Study 36052222 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable decompensated cirrhosis patients (n=507)
Number of subjects: 1736
Study 36052222 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model incorporating precipitants, systemic inflammation, and organ injuries
Number of subjects: 1736
Study 36052502 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide, a second-generation AR-targeted therapy
Number of subjects: 0
Study 36052732 — intervention group
Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV) at a dose of 1 × 10 7 TCID 50
Number of subjects: 0
Study 36052732 — intervention group
Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV) at a dose of 10 10 TCID 50
Number of subjects: 0
Study 36052732 — intervention group
Group type: COMPARATOR
Intervention: Vesicular stomatitis virus (VSV) at a dose of 1 × 10 8 TCID 50
Number of subjects: 0
Study 36052732 — intervention group
Group type: EXPERIMENTAL
Intervention: Morreton virus (MORV)
Number of subjects: 0
Study 36052740 — intervention group
Group type: EXPERIMENTAL
Intervention: HFpEF
Number of subjects: 3289
Study 36052740 — intervention group
Group type: COMPARATOR
Intervention: HFmrEF
Number of subjects: 3289
Study 36052740 — intervention group
Group type: COMPARATOR
Intervention: HFrEF
Number of subjects: 3289
Study 36052743 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejuveinix plus dexamethasone
Number of subjects: 0
Study 36052743 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 36053178 — intervention group
Group type: EXPERIMENTAL
Intervention: Decipher genomic classifier
Number of subjects: 226
Study 36053283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low test dose of pemetrexed (100 μg)
Number of subjects: 10
Study 36053283 — intervention group
Group type: COMPARATOR
Intervention: Renal function
Number of subjects: 10
Study 36053289 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS evaluation with an occlusion test after 8 hours of care
Number of subjects: 66
Study 36053289 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-derived parameters
Number of subjects: 66
Study 36053381 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR formulas
Number of subjects: 0
Study 36053381 — intervention group
Group type: COMPARATOR
Intervention: Iohexol plasma clearance
Number of subjects: 0
Study 36053449 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP) taken daily for up to 120 consecutive days
Number of subjects: 577
Study 36053449 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended regimen of ethinylestradiol/drospirenone (EE/DRSP)
Number of subjects: 577
Study 36053558 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based decision aid (DA) for treatment planning of SKMs
Number of subjects: 50
Study 36053558 — intervention group
Group type: COMPARATOR
Intervention: Existing web-based institutional website
Number of subjects: 50
Study 36053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension management in public and private centers
Number of subjects: 25890
Study 36053572 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection via web interface in Dacima Clinical Suite
Number of subjects: 25890
Study 36053624 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) in the first postnatal week
Number of subjects: 62145
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (n=1255)
Number of subjects: 16440
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (n=3857)
Number of subjects: 16440
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure (n=916)
Number of subjects: 16440
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PDA treatment (n=5721)
Number of subjects: 16440
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA incidence
Number of subjects: 16440
Study 36053632 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA diagnosis
Number of subjects: 16440
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention during the appointment
Number of subjects: 1341
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions and/or significant discussions
Number of subjects: 1341
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescriptions
Number of subjects: 1341
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests and/or medical imaging
Number of subjects: 1341
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled follow-up appointments
Number of subjects: 1341
Study 36053658 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals to other professionals
Number of subjects: 1341
Study 36053786 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin (AD) for 4 or 6 cycles based on interim PET response
Number of subjects: 34
Study 36053786 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin (AD)
Number of subjects: 34
Study 36053823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft
Number of subjects: 0
Study 36053875 — intervention group
Group type: EXPERIMENTAL
Intervention: Relmacabtagene autoleucel (Carteyva)
Number of subjects: 0
Study 36053905 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (n=407)
Number of subjects: 1540
Study 36053905 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/nab-paclitaxel (n=655)
Number of subjects: 1540
Study 36053966 — intervention group
Group type: EXPERIMENTAL
Intervention: Local stroke center group
Number of subjects: 1369
Study 36053966 — intervention group
Group type: COMPARATOR
Intervention: Thrombectomy-capable center group
Number of subjects: 1369
Study 36054234 — intervention group
Group type: EXPERIMENTAL
Intervention: pp65-specific TCR-T cell therapy
Number of subjects: 0
Study 36054234 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36054490 — intervention group
Group type: EXPERIMENTAL
Intervention: CV301 in combination with nivolumab (C1)
Number of subjects: 15
Study 36054490 — intervention group
Group type: EXPERIMENTAL
Intervention: CV301 in combination with pembrolizumab (C2)
Number of subjects: 15
Study 36054522 — intervention group
Group type: EXPERIMENTAL
Intervention: HPP patients with one ALPL variant
Number of subjects: 80
Study 36054522 — intervention group
Group type: EXPERIMENTAL
Intervention: HPP patients with two ALPL variants
Number of subjects: 80
Study 36054568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4720
Study 36054568 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline bilirubin
Number of subjects: 4720
Study 36054609 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaucher disease type 1 (GD1) patients
Number of subjects: 2123
Study 36055538 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz right hemisphere DLPFC rTMS
Number of subjects: 19
Study 36055922 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide
Number of subjects: 0
Study 36055922 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 0
Study 36055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition at birth (FFMI, FMI, BF%, BMI)
Number of subjects: 1200
Study 36055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity of BF% from birth to ∼5 y
Number of subjects: 1200
Study 36055960 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity of BMI from birth to ∼5 y
Number of subjects: 1200
Study 36055962 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary acrylamide intake (mean ± SD: 30.1 ± 21.9 µg/d)
Number of subjects: 80597
Study 36056179 — intervention group
Group type: EXPERIMENTAL
Intervention: Bermekimab with Nanoliposomal Irinotecan (Nal-Iri) and 5-Fluorouracil/Folinic Acid (5-FU/FA)
Number of subjects: 22
Study 36056287 — intervention group
Group type: EXPERIMENTAL
Intervention: Outgrowth endothelial cell-derived conditioned media (OEC-CM)
Number of subjects: 81
Study 36056317 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic yield
Number of subjects: 2268
Study 36056317 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic yield
Number of subjects: 2268
Study 36056317 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with endoscopic yield
Number of subjects: 2268
Study 36056317 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with histologic yield
Number of subjects: 2268
Study 36056317 — intervention group
Group type: EXPERIMENTAL
Intervention: Indications for EGD
Number of subjects: 2268
Study 36056321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological approach in pediatric age (98%)
Number of subjects: 106
Study 36056321 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-compatible ventilator availability
Number of subjects: 106
Study 36056321 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring tools availability
Number of subjects: 106
Study 36056321 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologist management
Number of subjects: 106
Study 36056321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated nurse presence
Number of subjects: 106
Study 36056348 — intervention group
Group type: EXPERIMENTAL
Intervention: Low education level
Number of subjects: 10000
Study 36056348 — intervention group
Group type: COMPARATOR
Intervention: High education level
Number of subjects: 10000
Study 36056624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with MEN2B
Number of subjects: 48
Study 36056720 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth access measures
Number of subjects: 2796
Study 36056720 — intervention group
Group type: COMPARATOR
Intervention: Internet access
Number of subjects: 2796
Study 36056720 — intervention group
Group type: COMPARATOR
Intervention: Computing device ownership
Number of subjects: 2796
Study 36056720 — intervention group
Group type: COMPARATOR
Intervention: Fitness tracker ownership
Number of subjects: 2796
Study 36056720 — intervention group
Group type: EXPERIMENTAL
Intervention: Computing device ownership for Chinese participants
Number of subjects: 2796
Study 36056720 — intervention group
Group type: COMPARATOR
Intervention: Internet access for Chinese participants
Number of subjects: 2796
Study 36056720 — intervention group
Group type: COMPARATOR
Intervention: Internet access for participants with other health insurance
Number of subjects: 2796
Study 36056877 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) torsion measured by cardiovascular magnetic resonance (CMR)
Number of subjects: 420
Study 36056877 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) torsion measured by CMR
Number of subjects: 420
Study 36056877 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of LV torsion to conventional prognostic factors
Number of subjects: 420
Study 36057175 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra-Zeneca vaccine and Sputnik V vaccine (complete vaccination)
Number of subjects: 576
Study 36057440 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based OSCE
Number of subjects: 36
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM(N) antibody levels in infected healthcare workers
Number of subjects: 769
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG(N) antibody levels in infected healthcare workers
Number of subjects: 769
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG(S) antibody levels in infected healthcare workers
Number of subjects: 769
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetics of IgM(N) and IgG(N) antibodies
Number of subjects: 769
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetics of IgG(S) antibodies
Number of subjects: 769
Study 36057544 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetics of IgM and IgG antibodies
Number of subjects: 769
Study 36057890 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (BV+CHP)
Number of subjects: 0
Study 36057890 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, prednisone, and vincristine)
Number of subjects: 0
Study 36058111 — intervention group
Group type: COMPARATOR
Intervention: Community sanitation coverage of at least one latrine per compound within 50m
Number of subjects: 360
Study 36058111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher community sanitation coverage
Number of subjects: 360
Study 36058784 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B27-driven altered antibody responses to gut microbiota
Number of subjects: 0
Study 36058784 — intervention group
Group type: EXPERIMENTAL
Intervention: Current literature and hypotheses on gut microbiota and HLA-B27-associated disease
Number of subjects: 0
Study 36058784 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for future well-controlled human studies
Number of subjects: 0
Study 36058810 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker use in treatment decisions
Number of subjects: 0
Study 36058810 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective trials and collaborative efforts
Number of subjects: 0
Study 36058829 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with all segments with maxLCBI > 400
Number of subjects: 1550
Study 36058829 — intervention group
Group type: COMPARATOR
Intervention: Patients with varying levels of maxLCBI
Number of subjects: 1550
Study 36058925 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated transdiagnostic, interdisciplinary group treatment delivered during 5 consecutive days.
Number of subjects: 42
Study 36059138 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg every 12 hours
Number of subjects: 18
Study 36059138 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion of ceftaroline 50 mg/h after a loading dose of 600 mg
Number of subjects: 18
Study 36059450 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (24 patients)
Number of subjects: 49
Study 36059450 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy (16 patients)
Number of subjects: 49
Study 36059450 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant targeted therapy (9 patients)
Number of subjects: 49
Study 36059523 — intervention group
Group type: EXPERIMENTAL
Intervention: tandem CD19-CD22 based CAR-T cells
Number of subjects: 33
Study 36060219 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory video intervention
Number of subjects: 0
Study 36060221 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplements and vitamin A-fortified foods
Number of subjects: 0
Study 36060221 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36060611 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaomi Mi Band for sleep monitoring
Number of subjects: 0
Study 36060678 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training with hyperbaric oxygen (HBO)
Number of subjects: 0
Study 36060678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 36061275 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management training (SMT)
Number of subjects: 0
Study 36061275 — intervention group
Group type: COMPARATOR
Intervention: Neurofeedback (NF)
Number of subjects: 0
Study 36061298 — intervention group
Group type: EXPERIMENTAL
Intervention: Alight app
Number of subjects: 63
Study 36061300 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating microRNAs (miRNAs) quantified using ID3EAL™ miRNA Discovery Platform
Number of subjects: 217
Study 36061300 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-relapsers)
Number of subjects: 217
Study 36061336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aficamten (≤50 mg single doses or ≤10 mg daily for 14 or 17 days)
Number of subjects: 0
Study 36061336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36061421 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator tape intervention, details on dosage and duration not available
Number of subjects: 0
Study 36061551 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting power/mass and E/e' ratio
Number of subjects: 475
Study 36061555 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology-guided PCI
Number of subjects: 1322
Study 36061555 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1322
Study 36061555 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-Guided PCI
Number of subjects: 1322
Study 36061598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day accelerated continuous theta burst stimulation (cTBS) treatment
Number of subjects: 7
Study 36061897 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately carbohydrate-restricted diet for 6 weeks
Number of subjects: 72
Study 36061897 — intervention group
Group type: COMPARATOR
Intervention: Fixed body weight loss
Number of subjects: 72
Study 36061986 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied over the primary motor cortex of the undamaged hemisphere
Number of subjects: 17
Study 36061986 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study 36061986 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy individuals
Number of subjects: 17
Study 36062026 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab followed by alemtuzumab sequential therapy
Number of subjects: 0
Study 36062046 — intervention group
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Number of subjects: 77
Study 36062144 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-domain exercise intervention (WE-BFit)
Number of subjects: 100
Study 36062144 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 36062451 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) with daily measurements of vital parameters under guidance of HF nurses.
Number of subjects: 1538
Study 36062451 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM) with daily measurements of vital parameters.
Number of subjects: 1538
Study 36062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethyllysine (TML)
Number of subjects: 2413
Study 36062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma TML
Number of subjects: 2413
Study 36062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma GBB
Number of subjects: 2413
Study 36062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma TMAO
Number of subjects: 2413
Study 36062477 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate
Number of subjects: 2413
Study 36062815 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKAs)
Number of subjects: 2012
Study 36062815 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs)
Number of subjects: 2012
Study 36062815 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulant treatment
Number of subjects: 2012
Study 36062815 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant therapy
Number of subjects: 2012
Study 36062815 — intervention group
Group type: EXPERIMENTAL
Intervention: MPI values
Number of subjects: 2012
Study 36062815 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores in MPI
Number of subjects: 2012
Study 36062869 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379 with itraconazole 200 mg (CYP3A inhibitor) for 21 days prior to dosing.
Number of subjects: 0
Study 36062869 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Number of subjects: 0
Study 36062869 — intervention group
Group type: COMPARATOR
Intervention: High-dose estrogen-based contraceptives with JNJ-56136379
Number of subjects: 0
Study 36062970 — intervention group
Group type: COMPARATOR
Intervention: Systemic corticosteroids plus intranasal corticosteroid/mucolytic/decongestant
Number of subjects: 30
Study 36062970 — intervention group
Group type: COMPARATOR
Intervention: Palmitoylethanolamide plus luteolin
Number of subjects: 30
Study 36063082 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 709
Study 36063082 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 709
Study 36063364 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroid spray
Number of subjects: 691
Study 36063364 — intervention group
Group type: COMPARATOR
Intervention: Intranasal corticosteroid drops
Number of subjects: 691
Study 36063533 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced HIV testing services with features such as everyday testing availability, health checks, and STI examinations.
Number of subjects: 740
Study 36063533 — intervention group
Group type: COMPARATOR
Intervention: Oral testing and provider-assisted confidential partner notification.
Number of subjects: 740
Study 36063832 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine with venetoclax
Number of subjects: 23
Study 36063832 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m²
Number of subjects: 23
Study 36063832 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 23
Study 36064386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab (200 mg) plus docetaxel (75 mg/m2)
Number of subjects: 30
Study 36064386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sintilimab plus docetaxel
Number of subjects: 30
Study 36064386 — intervention group
Group type: EXPERIMENTAL
Intervention: High PD-L1 expression in circulating tumor cells (CTC-PD-L1 ≥32.5%)
Number of subjects: 30
Study 36064386 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1 < 1% and CD8 ≥ 1% expression
Number of subjects: 30
Study 36064395 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (HL) tailored practices implemented by healthcare professionals (HCPs)
Number of subjects: 29
Study 36064395 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and training of HCPs about health literacy (HL)
Number of subjects: 29